Serotonin-related polymorphisms in TPH1 and HTR5A genes are not associated with escitalopram treatment response in korean patients with major depression

Neuropsychobiology

Volumn 69, Issue 4, 2014, Pages 210-219

  Kim, Yong Gu ^a   Chang, Hun Soo ^c   Won, Eun Soo ^a   Ham, Byung Joo ^a   Lee, Min Soo ^a,b  

^a Korea University College of Medicine   (South Korea)

^b Korea University   (South Korea)

^c Soonchunhyang University   (South Korea)

Author keywords

Escitalopram treatment response; Major depressive disorder; Serotonin 5A receptor; Tryptophan hydroxylase 1

Indexed keywords

ESCITALOPRAM; SEROTONIN; SEROTONIN 5A RECEPTOR; TRYPTOPHAN HYDROXYLASE; TRYPTOPHAN HYDROXYLASE 1; UNCLASSIFIED DRUG; ANTIDEPRESSANT AGENT; CITALOPRAM; SEROTONIN 5 RECEPTOR; SEROTONIN RECEPTOR; TPH1 PROTEIN, HUMAN;

ARTICLE; CLINICAL EVALUATION; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAMILTON SCALE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MULTIPLE LINEAR REGRESSION ANALYSIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; REMISSION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE; ASIAN CONTINENTAL ANCESTRY GROUP; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENETICS; KOREA; MALE; MIDDLE AGED; PHARMACOGENETICS; PSYCHOLOGICAL RATING SCALE; PSYCHOPHARMACOLOGY; STATISTICAL MODEL; TIME; ADULT; CHRONOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; GENE; GENE FUNCTION; HAMILTON DEPRESSION RATING SCALE; MENTAL PATIENT; PSYCHOPHARMACOTHERAPY; RECEPTOR GENE; SEROTONIN 5A RECEPTOR GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TRYPTOPHAN HYDROXYLASE 1 GENE;

ANTIDEPRESSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; KOREA; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PSYCHIATRIC STATUS RATING SCALES; PSYCHOPHARMACOLOGY; RECEPTORS, SEROTONIN; TIME FACTORS; TREATMENT OUTCOME; TRYPTOPHAN HYDROXYLASE;

EID: 84901733153     PISSN: 0302282X     EISSN: 14230224     Source Type: Journal    
DOI: 10.1159/000362241     Document Type: Article

References (45)

1. Ustun TB, Rehm J, Chatterji S, Saxena S, Trotter R, Room R, Bickenbach J: Multiple-informant ranking of the disabling effects of different health conditions in 14 countries. WHO/ NIH Joint Project CAR Study Group. Lancet 1999; 354: 111-115.
2. Wang HC, Yeh TL, Chang HH, Gean PW, Chi MH, Yang YK, Lu RB, Chen PS: TPH1 is associated with major depressive disorder but not with SSRI/SNRI response in Taiwanese patients. Psychopharmacology 2011; 213: 773-779.
3. Duffy A, Grof P, Robertson C, Alda M: The implications of genetics studies of major mood disorders for clinical practice. J Clin Psychiatry 2000; 61: 630-637.
4. Moncrieff J, Kirsch I: Efficacy of antidepressants in adults. BMJ (Clin Res Ed) 2005; 331: 155-157.
5. Thase ME: Applying antidepressant study results to clinical practice. J Clin Psychiatry 2012; 73:e21.
6. Masand PS: Tolerability and adherence issues in antidepressant therapy. Clin Ther 2003; 25: 2289-2304.
7. Viikki M, Kampman O, Illi A, Setala-Soikkeli E, Anttila S, Huuhka M, Nuolivirta T, Poutanen O, Mononen N, Lehtimaki T, Leinonen E: TPH1 218A/C polymorphism is associated with major depressive disorder and its treatment response. Neurosci Lett 2010; 468: 80-84.
8. Sullivan PF, Neale MC, Kendler KS: Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry 2000; 157: 1552-1562.
9. Porcelli S, Fabbri C, Serretti A: Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol 2012; 22: 239-258.
10. Kishi T, Fukuo Y, Yoshimura R, Okochi T, Kitajima T, Naitoh H, Umene-Nakano W, Nakamura J, Ozaki N, Iwata N: Pharmacogenetic study of serotonin 6 receptor gene with antidepressant response in major depressive disorder in the Japanese population. Hum Psychopharmacol 2010; 25: 481-486.
11. Kato M, Zanardi R, Rossini D, De Ronchi D, Okugawa G, Kinoshita T, Colombo C, Serretti A: 5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients. Psychiatry Res 2009; 167: 97-105.
12. Hoschl C, Svestka J: Escitalopram for the treatment of major depression and anxiety disorders. Expert Rev Neurother 2008; 8: 537-552.
13. Kirino E: Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability. Patient Pref Adher 2012; 6: 853-861.
14. Craig SP, Boularand S, Darmon MC, Mallet J, Craig IW: Localization of human tryptophan hydroxylase (TPH) to chromosome 11p15.3- p14 by in situ hybridization. Cytogenet Cell Genet 1991; 56: 157-159.
15. Zill P, Buttner A, Eisenmenger W, Moller HJ, Ackenheil M, Bondy B: Analysis of tryptophan hydroxylase I and II mRNA expression in the human brain: a post-mortem study. J Psychiatr Res 2007; 41: 168-173.
16. Kato M, Wakeno M, Okugawa G, Fukuda T, Azuma J, Kinoshita T, Serretti A: No association of TPH1 218A/C polymorphism with treatment response and intolerance to SSRIs in Japanese patients with major depression. Neuropsychobiology 2007; 56: 167-171.
17. Nakamura K, Sugawara Y, Sawabe K, Ohashi A, Tsurui H, Xiu Y, Ohtsuji M, Lin QS, Nishimura H, Hasegawa H, Hirose S: Late developmental stage-specific role of tryptophan hydroxylase 1 in brain serotonin levels. J Neurosci 2006; 26: 530-534.
18. Ham BJ, Lee BC, Paik JW, Kang RH, Choi MJ, Choi IG, Lee MS: Association between the tryptophan hydroxylase-1 gene A218C polymorphism and citalopram antidepressant response in a Korean population. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 104-107.
19. Nielsen DA, Jenkins GL, Stefanisko KM, Jefferson KK, Goldman D: Sequence, splice site and population frequency distribution analyses of the polymorphic human tryptophan hydroxylase intron 7. Brain Res Mol Brain Res 1997; 45: 145-148.
20. Jonsson EG, Goldman D, Spurlock G, Gustavsson JP, Nielsen DA, Linnoila M, Owen MJ, Sedvall GC: Tryptophan hydroxylase and catechol-O-methyltransferase gene polymorphisms: relationships to monoamine metabolite concentrations in CSF of healthy volunteers. Eur Arch Psychiatry Clin Neurosci 1997; 247: 297-302.
21. Jacobs BL, Azmitia EC: Structure and function of the brain serotonin system. Physiol Rev 1992; 72: 165-229.
22. Peroutka SJ: Serotonin receptor subtypes. CNS Drugs 1995; 4: 18-28.
23. Yu YW, Tsai SJ, Liou YJ, Hong CJ, Chen TJ: Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders. Eur Neuropsychopharmacol 2006; 16: 498-503.
24. Jin C, Xu W, Yuan J, Wang G, Cheng Z: Metaanalysis of association between the -1438A/G (rs6311) polymorphism of the serotonin 2A receptor gene and major depressive disorder. Neurol Res 2013; 35: 7-14.
25. Viikki M, Huuhka K, Leinonen E, Illi A, Setala- Soikkeli E, Huuhka M, Mononen N, Lehtimaki T, Kampman O: Interaction between two HTR2A polymorphisms and gender is associated with treatment response in MDD. Neurosci Lett 2011; 501: 20-24.
26. Yamada K, Hattori E, Iwayama Y, Ohnishi T, Ohba H, Toyota T, Takao H, Minabe Y, Nakatani N, Higuchi T, Detera-Wadleigh SD, Yoshikawa T: Distinguishable haplotype blocks in the HTR3A and HTR3B region in the Japanese reveal evidence of association of HTR3B with female major depression. Biol Psychiatry 2006; 60: 192-201.
27. Nelson D: 5-HT5 receptors. Curr Drug Targets CNS Neurol Disord 2004; 3: 53-58.
28. Grailhe R, Waeber C, Dulawa SC, Hornung JP, Zhuang X, Brunner D, Geyer MA, Hen R: Increased exploratory activity and altered response to LSD in mice lacking the 5-HT(5A) receptor. Neuron 1999; 22: 581-591.
29. Lambe EK, Fillman SG, Webster MJ, Shannon Weickert C: Serotonin receptor expression in human prefrontal cortex: balancing excitation and inhibition across postnatal development. PloS One 2011; 6:e22799.
30. Arias B, Collier DA, Gasto C, Pintor L, Gutierrez B, Valles V, Fananas L: Genetic variation in the 5-HT5A receptor gene in patients with bipolar disorder and major depression. Neurosci Lett 2001; 303: 111-114.
31. Shim JH, Paik JW, Oh JW, Kang RH, Lee HY, Lee MS: Association of the 5-HT5A receptor gene polymorphisms and citalopram response in Korean patients with major depressive disorder. Korean J Biol Psychiatry 2008; 15: 303-309.
32. Xu Z, Zhang Z, Shi Y, Pu M, Yuan Y, Zhang X, Li L, Reynolds GP: Influence and interaction of genetic polymorphisms in the serotonin system and life stress on antidepressant drug response. J Psychopharmacol (Oxf) 2012; 26: 349-359.
33. Birkett JT, Arranz MJ, Munro J, Osbourn S, Kerwin RW, Collier DA: Association analysis of the 5-HT5A gene in depression, psychosis and antipsychotic response. Neuroreport 2000; 11: 2017-2020.
34. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56.
35. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, Rush AJ, Weissman MM: Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991; 48: 851-855.
36. Menashe I, Rosenberg PS, Chen BE: PGA: power calculator for case-control genetic association analyses. BMC Genet 2008; 9: 36.
37. Kato M, Serretti A: Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 2010; 15: 473-500.
38. Yoshida K, Naito S, Takahashi H, Sato K, Ito K, Kamata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Tezuka T, Suzuki T, Ohkubo T, Sugawara K, Otani K: Monoamine oxidase: a gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 1279-1283.
39. Peters EJ, Slager SL, McGrath PJ, Knowles JA, Hamilton SP: Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry 2004; 9: 879-889.
40. Ham BJ, Lee MS, Lee HJ, Kang RH, Han CS, Choi MJ, Lee SH, Ryu SH: No association between the tryptophan hydroxylase gene polymorphism and major depressive disorders and antidepressant response in a Korean population. Psychiatr Genet 2005; 15: 299-301.
41. Kim YK, Yoon HK: Effect of serotonin-related gene polymorphisms on pathogenesis and treatment response in Korean schizophrenic patients. Behav Genet 2011; 41: 709-715.
42. Won ES, Chang HS, Lee HY, Ham BJ, Lee MS: Association between serotonin transporterlinked polymorphic region and escitalopram antidepressant treatment response in Korean patients with major depressive disorder. Neuropsychobiology 2012; 66: 221-229.
43. Kishi T, Yoshimura R, Kitajima T, Okochi T, Okumura T, Tsunoka T, Yamanouchi Y, Kinoshita Y, Kawashima K, Naitoh H, Nakamura J, Ozaki N, Iwata N: HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort. Neuromol Med 2010; 12: 237-242.
44. Anttila S, Kampman O, Illi A, Rontu R, Lehtimaki T, Leinonen E: Association between 5-HT2A, TPH1 and GNB3 genotypes and response to typical neuroleptics: a serotonergic approach. BMC Psychiatry 2007; 7: 22.
45. Lin E, Chen PS, Chang HH, Gean PW, Tsai HC, Yang YK, Lu RB: Interaction of serotonin- related genes affects short-term antidepressant response in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 1167-1172.